Imbruvica (Ibrutinib) Patent Expiration, LOE Window & CMS Spending

Imbruvica (Ibrutinib) by AbbVie: FDA Orange Book core substance LOE 2034-04-30 (last listed 2035-04-24), 1 AB generics, $2.36B 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN205552 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-04-30
Last Listed Patent or Exclusivity Date2035-04-24
Orange Book Patents (*PED Extensions)67 patents (33 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$2.36B
2024 Medicare Part D Spend$2.27B
2024 Medicaid Spend$89.6M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 22.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.